TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$172.5 Million

Arcutis Biotherapeutics, Inc.

Follow-on Offering

Bookrunner, August 2022

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (or The Company) is an early commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. The Company’s current portfolio is comprised of highly differentiated topical treatments with significant potential to treat immune-mediated dermatological diseases and conditions. Arcutis believes it has built the industry's leading platform for dermatologic product development. The Company’s strategy is to focus on validated biological targets, and to use its drug development platform and deep dermatology expertise to develop differentiated products that have the potential to address the major shortcomings of existing therapies in targeted indications.